Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05866848
Other study ID # CCBF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2021
Est. completion date June 1, 2021

Study information

Verified date May 2023
Source Escola Superior de Tecnologia da Saúde de Coimbra
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate in clinically healthy young people if: - after caffeine ingestion, there are variations in blood velocity of the middle cerebral arteries (VMCA), - this variation is dependent on the administered dose. Transcranial Doppler ultrasonography was used to record blood VMCA in three groups of 15 clinically healthy young adults each - no caffeine, low caffeine (45 mg) and high caffeine group (120 mg). Transcranial Doppler ultrasonography provided simultaneous bilateral VMCA measurements while subjects performed functional tests (hyperventilation and hypoventilation orders) and three cognitive activities (Test 1, short-term remembering, Test 2, solving a vocabulary problem, and Test 3, solving a math problem) each in 31-second tests with 1-minute rest between them. Participants were assessed before and 30 minutes after caffeine ingestion.


Description:

Were used in the study, Capsules dosed with 45mg and 120 mg of anhydrous caffeine and flour capsules as a placebo. In the preparation of the capsules, a semi-automatic capsulator No. 0 (Capsunorm® by Tecnyfarma®) were used, colorless hard gelatin capsules No. 0 by Acopharma® and anhydrous caffeine (Biochem®, C.A.S. 58-08-2). Viasys Sonara transcranial Doppler unit and a 2 MHz probe were used to sample the middle cerebral artery at depths of 60 millimeters, using emission doppler pulsed performing spectral analysis in real time. Two probes (bilaterally) of 2MHz were placed at a depth between 55 and 60 mm, thus making it possible to analyse both middle cerebral arteries simultaneously. Each participant was asked not to ingest caffeine and exercise vigorously for at least 12 hours before the assessment. In the case of smokers, they were also asked not to smoke for at least 2 hours before the evaluation. The laboratory had medium luminosity, silent and controlled temperature (23º/24ºC). To avoid inter-observer errors, all examinations were performed by the same investigator who was not aware of what dose was/had been administered to the participant. Subjects were tested while seated in a reclining chair located in a dimly lit, sound-attenuated room and performed the activities with their eyes closed.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date June 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - clinically healthy young people Exclusion Criteria: - Individuals with hypertension, high cholesterol, diabetes, arrhythmias, carotid sinus syndrome, severe carotid stenosis and who were in an unstable clinical situation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Placebo
Flour capsules as a placebo.
Anhydrous caffeine (45mg)
Capsules dosed with 45mg of anhydrous caffeine.
Anhydrous caffeine (120mg)
Capsules dosed with 120mg of anhydrous caffeine.

Locations

Country Name City State
Portugal Coimbra Health School Coimbra

Sponsors (1)

Lead Sponsor Collaborator
Escola Superior de Tecnologia da Saúde de Coimbra

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Mean Velocity (Basal) Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Mean Velocity (Hypoventilation) By performing Hypoventilation, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Mean Velocity (Hyperventilation) By performing Hyperventilation, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Mean Velocity (Short-term memory test) With short-term memory test, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Mean Velocity (Vocabulary problem) With solving vocabulary problems, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Mean Velocity (Math problem.) With solving math problems, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Basal) Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Hypoventilation) By performing Hypoventilation, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Hyperventilation) By performing Hyperventilation, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Short-term memory test) With short-term memory test, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Vocabulary problems) With solving vocabulary problems, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Peak systolic velocity (Math problems) With solving math problems, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Basal) Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Hypoventilation) By performing Hypoventilation, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Hyperventilation) By performing Hyperventilation, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Short-term memory test) With short-term memory test, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Vocabulary problems) With solving vocabulary problems, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Primary Changes in Vend-diastolic velocity (Math problems) With solving math problems, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Basal) Changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Hypoventilation) By performing Hypoventilation, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Hyperventilation) By performing Hyperventilation, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Short-term memory test) With short-term memory test, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Vocabulary problems) With solving vocabulary problems, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
Secondary Changes in Heart Rate (Math problems) With solving math problems, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion. 30 minutes
See also
  Status Clinical Trial Phase
Completed NCT03697499 - Effects of Fish Oil in Alleviating Health Hazards Associated With Ozone Exposure N/A
Active, not recruiting NCT04153539 - Acute Health Effects of Traffic-Related Air Pollution Exposure N/A
Completed NCT04579497 - Temperature-dependent Changes in Cardiovascular Parameters During Warm Water Footbaths in Healthy Women N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT02977390 - Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM N/A
Not yet recruiting NCT06076629 - Acute Health Effects of Low Temperature Exposure N/A
Completed NCT05289817 - Effects of Transcutaneous Electrical Stimulation on the Autonomous Nerve System in Healthy Young People N/A
Completed NCT04209738 - Changes in Cardiovascular and Sleep Quality Parameters Under Eurythmy Therapy and Tai Chi in Comparison to Standard Care - A Substudy of the ENTAiER Trial
Active, not recruiting NCT05727332 - Vascular Adaptations to Single-Sprint Training N/A
Completed NCT02979327 - Cardiovascular Effects of Adderall in Healthy Adults. Early Phase 1
Completed NCT01940822 - Cardiovascular Effects of Energy Drinks in Healthy Adults N/A
Completed NCT03395977 - Uric Acid Effects on Endothelium and Oxydative Stress N/A
Completed NCT03810118 - Fluid Challenge Infusion and Response N/A